{"disease":{"id":"fgf-amplification","name":"fgf amplification"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04526106","title":"REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"Elevar Therapeutics","has_results":false},{"nct_id":"NCT01004224","title":"A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07285434","title":"Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer","phase":"EARLY_PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":90,"lead_sponsor_name":"Biogenea Pharmaceuticals Ltd.","has_results":false},{"nct_id":"NCT04024436","title":"A Study of TAS-120 in Patients With Metastatic Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":64,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT05859477","title":"Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":23,"lead_sponsor_name":"Kidney Cancer Research Bureau","has_results":false},{"nct_id":"NCT06022289","title":"Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT04096417","title":"Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":14,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT05052372","title":"Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib","phase":"","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT02706691","title":"BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"University of Chicago","has_results":true}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}